1
|
Tauziède-Espariat A, Uro-Coste E, Sievers P, Nicaise Y, Mariet C, Siegfried A, Pierron G, Guillemot D, Benzakoun J, Pallud J, Roques M, Bonneville F, Larrieu-Ciron D, Chaynes P, Saffroy R, Hamelin J, Hasty L, Métais A, Chrétien F, Kool M, Gojo J, Varlet P. CNS tumor with EP300::BCOR fusion: discussing its prevalence in adult population. Acta Neuropathol Commun 2023; 11:26. [PMID: 36782314 PMCID: PMC9926824 DOI: 10.1186/s40478-023-01523-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Accepted: 01/24/2023] [Indexed: 02/15/2023] Open
Abstract
The Central Nervous System (CNS) tumor with BCOR internal tandem duplication (ITD) has recently been added as a novel embryonal histomolecular tumor type to the 2021 World Health Organization (WHO) Classification of CNS Tumors. In addition, other CNS tumors harboring a BCOR/BCORL1 fusion, which are defined by a distinct DNA-methylation profile, have been recently identified in the literature but clinical, radiological and histopathological data remain scarce. Herein, we present two adult cases of CNS tumors with EP300::BCOR fusion. These two cases presented radiological, histopathological, and immunohistochemical homologies with CNS tumors having BCOR ITD in children. To compare these tumors with different BCOR alterations, we performed a literature review with a meta-analysis. CNS tumors with EP300::BCOR fusion seem to be distinct from their BCOR ITD counterparts in terms of age, location, progression-free survival, tumor growth pattern, and immunopositivity for the BCOR protein. CNS tumors from the EP300::BCOR fusion methylation class in adults may be added to the future WHO classification.
Collapse
Affiliation(s)
- Arnault Tauziède-Espariat
- Department of Neuropathology, GHU Paris - Psychiatry and Neuroscience, Sainte-Anne Hospital, 1, Rue Cabanis, 75014, Paris, France. .,Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR S1266, INSERM, IMA-BRAIN, Paris, France. .,Université de Paris, Paris, France.
| | - Emmanuelle Uro-Coste
- grid.411175.70000 0001 1457 2980Department of Pathology, Toulouse University Hospital, Toulouse, France ,grid.468186.5Cancer Research Center of Toulouse (CRCT), INSERM U1037, Toulouse, France ,grid.15781.3a0000 0001 0723 035XUniversité Paul Sabatier, Toulouse III, Toulouse, France
| | - Philipp Sievers
- grid.5253.10000 0001 0328 4908Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany ,grid.7497.d0000 0004 0492 0584Clinical Cooperation Unit Neuropathology, German Cancer Research Center DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany
| | - Yvan Nicaise
- grid.411175.70000 0001 1457 2980Department of Pathology, Toulouse University Hospital, Toulouse, France ,grid.468186.5Cancer Research Center of Toulouse (CRCT), INSERM U1037, Toulouse, France ,grid.15781.3a0000 0001 0723 035XUniversité Paul Sabatier, Toulouse III, Toulouse, France
| | - Cassandra Mariet
- grid.414435.30000 0001 2200 9055Department of Neuropathology, GHU Paris - Psychiatry and Neuroscience, Sainte-Anne Hospital, 1, Rue Cabanis, 75014 Paris, France ,grid.5842.b0000 0001 2171 2558Université de Paris, Paris, France
| | - Aurore Siegfried
- grid.411175.70000 0001 1457 2980Department of Pathology, Toulouse University Hospital, Toulouse, France ,grid.468186.5Cancer Research Center of Toulouse (CRCT), INSERM U1037, Toulouse, France ,grid.15781.3a0000 0001 0723 035XUniversité Paul Sabatier, Toulouse III, Toulouse, France
| | - Gaëlle Pierron
- grid.418596.70000 0004 0639 6384Paris-Sciences-Lettres, Curie Institute Research Center, INSERMU830 Paris, France ,grid.418596.70000 0004 0639 6384Laboratory of Somatic Genetics, Curie Institute Hospital, Paris, France
| | - Delphine Guillemot
- grid.418596.70000 0004 0639 6384Paris-Sciences-Lettres, Curie Institute Research Center, INSERMU830 Paris, France
| | - Joseph Benzakoun
- grid.7429.80000000121866389Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR S1266, INSERM, IMA-BRAIN, Paris, France ,grid.414435.30000 0001 2200 9055Department of Radiology, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, Paris, France
| | - Johan Pallud
- grid.7429.80000000121866389Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR S1266, INSERM, IMA-BRAIN, Paris, France ,grid.5842.b0000 0001 2171 2558Université de Paris, Paris, France ,grid.414435.30000 0001 2200 9055Department of Neurosurgery, GHU Paris-Psychiatrie et Neurosciences, Sainte-Anne Hospital, Paris, France
| | - Margaux Roques
- grid.414282.90000 0004 0639 4960Department of Radiology, Purpan University Hospital, Toulouse, France
| | - Fabrice Bonneville
- grid.414282.90000 0004 0639 4960Department of Radiology, Purpan University Hospital, Toulouse, France
| | - Delphine Larrieu-Ciron
- grid.411175.70000 0001 1457 2980Department of Neurology, Toulouse University Hospital, Toulouse, France ,grid.488470.7Department of Medical Oncology, IUCT-Oncopole, Toulouse, France
| | - Patrick Chaynes
- grid.411175.70000 0001 1457 2980Department of Neurosurgery, Toulouse University Hospital, Toulouse, France
| | - Raphaël Saffroy
- grid.413133.70000 0001 0206 8146Department of Biochemistry and Oncogenetic, Paul Brousse Hospital, Villejuif, France
| | - Jocelyne Hamelin
- grid.413133.70000 0001 0206 8146Department of Biochemistry and Oncogenetic, Paul Brousse Hospital, Villejuif, France
| | - Lauren Hasty
- grid.414435.30000 0001 2200 9055Department of Neuropathology, GHU Paris - Psychiatry and Neuroscience, Sainte-Anne Hospital, 1, Rue Cabanis, 75014 Paris, France
| | - Alice Métais
- grid.414435.30000 0001 2200 9055Department of Neuropathology, GHU Paris - Psychiatry and Neuroscience, Sainte-Anne Hospital, 1, Rue Cabanis, 75014 Paris, France ,grid.7429.80000000121866389Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR S1266, INSERM, IMA-BRAIN, Paris, France ,grid.5842.b0000 0001 2171 2558Université de Paris, Paris, France
| | - Fabrice Chrétien
- grid.414435.30000 0001 2200 9055Department of Neuropathology, GHU Paris - Psychiatry and Neuroscience, Sainte-Anne Hospital, 1, Rue Cabanis, 75014 Paris, France ,grid.5842.b0000 0001 2171 2558Université de Paris, Paris, France
| | - Marcel Kool
- grid.510964.fHopp Children’s Cancer Center (KiTZ), Heidelberg, Germany ,grid.7497.d0000 0004 0492 0584Division of Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany ,grid.487647.ePrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - Johannes Gojo
- grid.22937.3d0000 0000 9259 8492Department of Pediatric and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - Pascale Varlet
- grid.414435.30000 0001 2200 9055Department of Neuropathology, GHU Paris - Psychiatry and Neuroscience, Sainte-Anne Hospital, 1, Rue Cabanis, 75014 Paris, France ,grid.7429.80000000121866389Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR S1266, INSERM, IMA-BRAIN, Paris, France ,grid.5842.b0000 0001 2171 2558Université de Paris, Paris, France
| | | |
Collapse
|
2
|
Gojo J, Kjaersgaard M, Zezschwitz BV, Capper D, Tietze A, Kool M, Haberler C, Pizer B, Hoff KV. Rare embryonal and sarcomatous central nervous system tumours: State-of-the art and future directions. Eur J Med Genet 2023; 66:104660. [PMID: 36356895 DOI: 10.1016/j.ejmg.2022.104660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Revised: 10/06/2022] [Accepted: 11/04/2022] [Indexed: 11/09/2022]
Abstract
The introduction of molecular methods into the diagnostics of central nervous system (CNS) tumours and the subsequent deciphering of their molecular heterogeneity has resulted in a significant impact on paediatric neurooncology. Particularly in the field of rare embryonal and sarcomatous CNS tumours, novel tumour types have been delineated and introduced in the recent 5th edition of the WHO classification of CNS tumours. The rarity and novelty of these tumour types result in diagnostic and therapeutic challenges. Apart from distinct histopathological and molecular features, these tumour types exhibit characteristic clinical properties and require different therapeutic approaches for optimal patient management. However, based on the limited availability of clinical data, current therapeutic recommendations have to be based on data from small, predominantly retrospective patient cohorts. Within this article, we provide guidance for diagnostic work-up and clinical management of rare CNS embryonal tumours ('embryonal tumour with multi-layered rosettes', ETMR; 'CNS neuroblastoma, FOXR2-activated', CNS NB-FOXR2; 'CNS tumour with BCOR-ITD, CNS BCOR-ITD) and rare CNS sarcomatous tumours ('primary intracranial sarcoma, DICER1-mutant', CNS DICER1; 'CIC-rearranged sarcoma', CNS CIC). By emphasizing the significant consequences on patient management in paediatric CNS tumours, we want to encourage wide implementation of comprehensive molecular diagnostics and stress the importance for joint international efforts to further collect and study these rare tumour types.
Collapse
Affiliation(s)
- Johannes Gojo
- Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany; Division of Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
| | - Mimi Kjaersgaard
- Department of Paediatrics and Adolescent Medicine, Children and Adolescents with Cancer and Hematological Diseases, Rigshospitalet, Copenhagen, Denmark
| | - Barbara V Zezschwitz
- Department of Paediatric Oncology and Haematology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt, Universität zu Berlin, Germany
| | - David Capper
- Department of Neuropathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Anna Tietze
- Institute of Neuroradiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
| | - Marcel Kool
- Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany; Division of Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
| | - Christine Haberler
- Division of Neuropathology and Neurochemistry, Department of Neurology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | | | - Katja V Hoff
- Department of Paediatric Oncology and Haematology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt, Universität zu Berlin, Germany; Department of Paediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
| |
Collapse
|